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Simple Summary: Chronic lymphocytic leukaemia (CLL) is the most frequent type of leukaemia
with a highly variable presentation, clinical course, and outcome. The overall aim of our study was to
determine the clinical and functional significance of two B-cell regulators, BACH2 and BCL6, in CLL.
The results showed that CLL patients expressing low levels of BACH2 and BCL6 RNA had a shorter
overall survival (OS). Their low RNA expression was associated with a shorter overall survival of
immunoglobulin heavy chain variable region-mutated (IGHV-M) CLL patients, as well as those with
11q and 13q deletions. Further, co-immunoprecipitation and mass spectrometry studies from MEC-1
CLL cells showed no direct interaction between BACH2 and BCL6, but shared protein networks
that are involved in ubiquitination mediated B-cell receptor functions, nucleic acid metabolism,
protein degradation, and homeostasis in CLL biology. Taken together, this study reports BACH2 as a
potential prognosticator and indicates the protein networks influenced by BCL6 and BACH2 in CLL.
Abstract: Chronic lymphocytic leukaemia (CLL) is a heterogeneous disease with a highly variable
clinical outcome. There are well-established CLL prognostic biomarkers that have transformed
treatment and improved the understanding of CLL biology. Here, we have studied the clinical
significance of two crucial B cell regulators, BACH2 (BTB and CNC homology 1, basic leucine zipper
transcription factor 2) and BCL6 (B-cell CLL/lymphoma 6), in a cohort of 102 CLL patients and
determined the protein interaction networks that they participate in using MEC-1 CLL cells. We
observed that CLL patients expressing low levels of BCL6 and BACH2 RNA had significantly shorter
overall survival (OS) than high BCL6- and BACH2-expressing cases. Notably, their low expression
specifically decreased the OS of immunoglobulin heavy chain variable region-mutated (IGHV-M)
CLL patients, as well as those with 11q and 13q deletions. Similar to the RNA data, a low BACH2
protein expression was associated with a significantly shorter OS than a high expression. There was
no direct interaction observed between BACH2 and BCL6 in MEC-1 CLL cells, but they shared protein
networks that included fifty different proteins. Interestingly, a prognostic index (PI) model that we
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generated, using integrative risk score values of BACH2 RNA expression, age, and 17p deletion
status, predicted patient outcomes in our cohort. Taken together, these data have shown for the first
time a possible prognostic role for BACH2 in CLL and have revealed protein interaction networks
shared by BCL6 and BACH2, indicating a significant role for BACH2 and BCL6 in key cellular
processes, including ubiquitination mediated B-cell receptor functions, nucleic acid metabolism,
protein degradation, and homeostasis in CLL biology.
Keywords: chronic lymphocytic leukaemia (CLL); BACH2; BCL6; prognosticator; tumour suppressor;
coimmunoprecipitation and proteomics
1. Introduction
Chronic lymphocytic leukaemia (CLL) is the most prevalent leukaemia among elderly
people in Western countries, showing highly variable outcomes [1]. In contrast to other
mature B-cell malignancies, the immunoglobulin heavy chain variable region (IGHV)
genes in CLL are either unmutated or somatically mutated and are related to a poor or
favourable outcome, respectively [2,3]. Although the cellular origin of CLL remains unclear,
unmutated CLL (U-CLL) is likely to arise from pre-germinal centre (GC) CD5+ CD27−
B-cells [4]. These cells originate from naive B-cells or a separate lineage of precursor
B-cells that have not encountered antigen to form a GC [4]. In contrast, mutated CLL
(M-CLL) appears to originate from post-germinal centre CD5+ CD27+ B-cells, which are
transcriptionally similar to memory B-cells that have undergone the GC reaction [5,6].
Despite antigen engagement and intact B-cell-receptor (BCR) signalling, CLL cells fail to
undergo terminal differentiation.
The transcriptional repressor, BACH2, is required for the somatic hypermutation
(SHM) and class switch recombination (CSR) of antibody genes, GC formation, and the
inhibition of plasma cell (PC) differentiation in B-cells [7–9]. BACH2, in co-operation
with BCL6, regulates GC B-cell fate through transcriptional and other biochemical mecha-
nisms [10,11]. Double heterozygous Bcl6−/+ Bach2−/+ mice exhibit a profound reduction
in GC formation in response to T-cell dependent antigen immunization [10]. In GC B-cells,
both BACH2 and BCL6 proteins are upregulated, with the stability of the BACH2 protein
regulated by BCL6 [10]. Interaction between BACH2 and BCL6 represses the transcription
of PRDM1 (PR domain containing 1, with ZNF domain), a key driver of plasma cell differen-
tiation [10]. Interestingly, the ratio of BACH2:BCL6 expression levels represent a significant
predictor of outcome in acute lymphoblastic leukaemia (ALL) [12]. In diffuse large B-cell
lymphoma (DLBCL), BACH2 mutations occur in about 5% [13] and BACH2 expression is
a predictor of an inferior outcome in the DLBCL high-risk group [14]. Moreover, BACH2
(induced by c-Rel/NF-κB) functions as a tumour suppressor in the early stages of B-cell
lymphoma development [15]. Recently, when the mRNA expression of BACH2 was studied
in untreated CLL patients with age-matched healthy donors, BACH2 mRNA expression
was shown to be reduced in CD4+ T-cells, CD8+ T-cells, and leukemic B-cells [16]. Here,
we have investigated the prognostic role of BCL6 and BACH2 in a CLL patient cohort.
Further, we have determined the relationship between them in MEC-1 CLL cells, using
co-immunoprecipitation (Co-IP) and mass spectrometry.
2. Materials and Methods
This retrospective study included 102 CLL patients following informed consent. Pa-
tients were selected based on the availability of fresh samples, clinical and cytogenetic data,
as well as overall survival data up to June 2015. This study cohort is heterogeneous, re-
flecting the diversity typically found among CLL patients. Samples were obtained through
the Newcastle Biobank (17/NE/0361). All patients were diagnosed with CLL according
to World Health Organization (WHO) criteria. RNA and protein extraction, qRT-PCR,
Western blot, and statistical analysis from patient samples were performed using standard
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techniques, as detailed in the Supplementary Materials. The in vitro protein localisation
and interaction studies in MEC-1 cells are also included in the Supplementary Materials.
3. Results
3.1. BACH2 and BCL6 Low RNA Expression Predicts Shorter Overall Survival in CLL
The total RNA and protein expression of BACH2 and BCL6 were measured in a
cohort of 102 and 91 among 102 CLL patients (Table 1 and S1), respectively. Expression
showed a high variability between CLL samples (Figures 1, S1 and S2). Receiver operating
characteristic (ROC) analysis was used to assign “high” and “low” expression sets (Figure
S2 and Table S2, showing the number of patients in each group of ROC analyses). A positive
correlation was found between BACH2 RNA and protein levels (Figure S3A), whereas
BCL6 RNA expression did not correlate with its protein levels (Figure S3B), possibly due to
the very low expression levels of BCL6 in CLL. Overall, BCL6 median expression was seven
times lower than BACH2 (Figure 1). However, the correlation between RNA and protein
expression data followed a similar trend, although not statistically significant (Figure S3).
Table 1. Clinical and molecular characteristics of the CLL cohort.
Characteristics, n = 102 Unless Stated N %
Age ≥ 65 31 62
Male 71 69.6
TP53 gene status n = 100
M 12 12
UM 88 88
ZAP70 status n = 19
>20% 9 47.4
<20% 10 52.6
CD38 status n = 36
>20% 13 36.1
<20% 23 63.9
Treatment status n = 102
Treated 35 34.3
Untreated 67 65.7
CLL expressing low levels of the BACH2 and BCL6 RNA had a significantly shorter
overall survival (OS) than those expressing high levels (p-value = 0.005 and p-value = 0.04,
respectively) (Figures 2 and 3). In relation to protein expression, low BACH2 protein levels
also predicted a shorter OS (Figure 4A), whereas low BCL6 protein showed only a trend
towards a reduced OS (Figure S4). These findings differed from previous observations of
higher expression of BCL6 correlating with a shorter treatment-free interval (TFI) in early-
stage CLL [17]. While our cohort was more representative of a general CLL population
(Tables 1 and 2), it included a limited amount of data on the time to first treatment and
progression-free survival of the cohort. Therefore, we limited our analyses to the overall
survival in this study.
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Table 2. Clinical and molecular characteristics of the CLL cohort including treatment status.
Binet Stage n = 90 N % Treated % Untreated %
A 49 54.4 10 20.4 39 79.6
B 16 17.8 7 43.8 9 56.3
C 25 27.8 16 64.0 9 36.0
IGHV status n = 63 Treated Untreated
M 38 60.3 17 44.7 21 55.3
UM 25 39.7 7 28.0 18 72.0
Cytogenetics n = 101 Treated Untreated
13q 62 61.4 21 33.9 41 66.1
11q 20 19.8 11 55.0 9 45.0
12+ 6 5.9 4 66.7 2 33.3
17p 8 7.9 1 12.5 7 87.5
Normal karyotype 24 23.8 18 75.0 6 25.0
Cytogenetics n = 101 BACH2 High BCL6 High
13q 62 61.4 35 56.5 42 67.7
11q 20 19.8 12 60.0 14 70.0
12+ 6 5.9 2 33.3 4 66.7
17p 8 7.9 3 37.5 4 50.0
Normal karyotype 24 23.8 12 50.0 15 62.5
M—mutated; UM—unmutated.
When the study cohort was separated based on treatment status (Tables 2, S1 and S2),
the low expression of BACH2 RNA had a significantly shorter OS than those expressing
high levels in the treatment naïve cohort, indicating BACH2 as a potential prognosticator
(Figure S5). The low BCL6 protein expression based on OS analyses showed only a trend
towards a reduced OS in the treatment naïve cohort but was not statistically significant.
Similarly, when previously treated patients were analysed, the same trend of low levels
of BACH2 and BCL6 expression corresponding to a shorter OS was observed (Figure S5).
However, the p-value was not significant, possibly due to the lower number of data points.
It is important to note that the treatment naïve patient numbers within the high and low
expressing groups of BACH2 and BCL6, separated based on the ROC analyses, included a
similar number of treated and untreated patients. Among the 67 treatment naïve patients,
low and high BACH2 expressing patients included were 30 and 37, respectively. Similarly,
within the CLL treated subgroup, the BACH2 low and high expression patients included
15 and 20, respectively, demonstrating that the high and low BACH2 expression groups
were balanced.
For survival analyses of the treatment naïve cohort, it was evident that low BACH2 as
well as BCL6 protein expression predicts a shorter survival rate, with statistical significance
(Figure 5A,B). Similarly, in the previously treated cohort, OS was also shorter when BACH2
protein expression was low compared to high expression, but this was not observed
for BCL6 (Figure 5C,D). Therefore, the data strongly suggest BACH2 as a promising
prognosticator in CLL.
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3.2. BACH2 and BCL6 Low RNA Expres ion Predicts Shorter Overall Survi al in IGHV-M, 13q-,
and 11q-Deleted Patient Subgroups of CLL
BACH2 and BCL6 low RNA expression also predicted a poor outcome in IGHV-M
patients (Figures 2B and 3B), whereas low BACH2 protein levels showed only a trend
towards a reduced OS in this subgroup (Figure 4B). Intriguingly, in the GC environment,
somatic mutations in the 5′-intronic region of BCL6 occurred in a similar manner to IGHV
somatic hypermutation in CLL [18]. Although BCL6 mutations appeared not to influence
its expression, these mutations are regarded as a marker of B-cell transit through the GC, as
they occur frequently in normal memory B-cells [18,19]. We found no significant correlation
between expression levels of BACH2 and BCL6 with the common CLL prognostic factors,
including clinical staging, age, and cytogenetic abnormalities (13q14, 11q23, and 17p13
deletions), but survival analysis showed that a low RNA expression of BACH2 and BCL6
was related to a poor outcome in the 13q- (Figures 2C and 3C) and 11q-deleted subgroups
(Figures 2D and 3D). Low BACH2 protein levels predicted a shorter OS in 13q-deleted
patients (Figure 4C), whereas BACH2 and BCL6 protein levels showed no impact on
survival in 11q-deleted CLL (Figures 4D and S4D). The loss of 13q14.3 is the most common
chromosomal aberration in CLL, accounting for 40–60% and, as the sole abnormality, it is
reported to be a good prognostic indicator [20]. In this subgroup, further reduced survival
was associated with low levels of BACH2 RNA, as well as protein (Figures 2C and 4C).
Cancers 2022, 14, 23 8 of 16
3.3. BACH2 Is a Promising Independent and Integrative Predictor of Outcome for CLL
The multivariate analysis confirmed the findings from the univariate analysis (Table S3),
revealing that the prognostic value of BACH2 RNA expression, in terms of OS, was inde-
pendent of age and 17p deletion status—two of the most reliable prognostic factors in CLL
(Table S3C). The IGHV mutational status was highly significant in both the univariate and
multivariate analyses. Further, when the multivariate analysis including BACH2 and BCL6
RNA expression, age, 17p status, treatment status, BACH2, and BCL6 protein expression
was performed, the data verified the independent prognostic value of low BACH2 expres-
sion (Tables S4 and S5). However, BACH2 expression was not a strong prognosticator when
all covariates were considered within the same model (Table S4). Moreover, a prognostic
index (PI) model (Figure 6A) generated using integrative risk score values of BACH2 RNA
expression, age, and 17p deletion status predicted outcome in our cohort (Figure 6). Overall,
the hazard ratio of comparing low risk cases with PI ≥ 2.60 to high-risk cases with PI < 2.60
was 4.074 (1.568–10.655), with a p-value of 0.004 (Figure 6B). This observation suggested
that BACH2 could be a promising independent and integrative predictor of outcome for
CLL, although further validation in a larger cohort is essential to confirm BACH2 as a
clinically significant prognosticator in CLL.
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on the integrative risk score values. The independent prognostic variables associate it ere
confirmed by multivariate analysis using the Cox proportional hazards model. (A) prognostic index
model was established based on independent variables that were significantly associated with OS in
the multivariate analysis (Table S3C). The PI of 2.60 was established as the optimal cut-point for this
analysis. (B) Overall, the hazard ratio of comparing cases with PI ≥ 2.60 to cases with PI < 2.60 is
4.074 (1.568–10.655) with a p-value of 0.004. GR and HR are good and high risk, respectively.
Additionally, we found that BACH2 RNA expression was negatively correlated with
CD38 expression (Pearson’s r = −0.418, p-value = 0.011) (Table S3A), which is a marker for
an unfavourable prognosis in CLL, which correlates with the BCR signalling response, acti-
vation, and proliferation [21]. BCL6 inhibits the expression of p53 and regulates the DNA
damage-induced apoptotic responses in GC B-cells [22–24]; thus, we also studied the link
between TP53 mutations and RNA expressions of BCL6 and BACH2, which showed no cor-
relation, implying TP53-independent functions for these regulators in CLL (Table S3A,B).
3.4. Mapping of BACH2 and BCL6 Mediated Signalling
We identified a positive correlation between BCL6 and BACH2 expression (Figure S6),
suggesting a possible concerted action in CLL. This finding was in agreement with the
cooperative function previously reported between BCL6 and BACH2 in GC B-cells [10].
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Furthermore, we investigated BCL6/BACH2 subcellular localisation, using immunoflu-
orescence and molecular interaction through reciprocal co-immunoprecipitation (co-IP)
followed by Orbitrap mass spectrometry analyses in MEC-1 CLL cells. Immunofluores-
cence analyses of BACH2 (green) and BCL6 (red) showed that BACH2 was predominantly
localised within the cytoplasm, whereas BCL6 was found in both the cytoplasm and nucleus
in MEC-1 CLL cells (Figure S7). The co-immunoprecipitation data showed no co-IP of BCL6
and BACH2 proteins (Figure 7A), while further proteomic analyses by mass spectrome-
try confirmed a lack of direct interaction between them under the analysed conditions.
Nevertheless, 50 proteins co-precipitated with BACH2 and BCL6, showing an extensively
shared protein network between them (Figure 7 and Table S6). The number of proteins that
isolated exclusively with BACH2 and BCL6 were 10 and 9, respectively (Table S7).
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detected from the co-immunoprecipitation and subsequent MS studies. (A) I munoprobing of BCL6
presence in co-immunoprecipitation (Co-IP) obtained with a plication of anti-BCL6, anti-BACH2,
and anti-IgG (control) in EC-1 cells (uncropped WB original image see Figure S9), (B) identification
of proteins interacting with BCL6 or BACH2 with mass spectrometry (MS)—Orbitrap analyses, and
(C) protein–protein interaction networks of BACH2 and BCL6.
Among the 50 identified interaction partners, 28 proteins were localised in the cy-
toplasm, while 7 w re in the cell periphery/membrane (DYNC1H1, COPB1, ARHGD1B,
SFXN1, RRBP1, I , . t i teractors display catalytic activity,
of which 13 are enzymes that catalyse metabolic interconversion (GANAB, NASA, PP 1,
AK2, TALDO1, PRDX6, GOT1, GOT2, ECH1, MT-CO2, PLCG2, ACO2, RPN1) (Figure S8
and Table S8).
Several c t e eukaryotic 26S proteasome complex that re part of the wo
subcomplexes—the 20S core particle (CP) and the 19S regulatory particle [25]—are identi-
fied as interaction partners of BACH2 and BCL6. BACH2-specific and shared interaction
partners include PSMD1, PSMD14, KIAA0368, PSMD4, PSMA1, proteasome adapter and
scaffold proteins (ECPAS), RAD23B, ABCE1, and USP48. The ubiquitin-mediated protein
degradation pathway is one of the major regulatory processes in CLL that regulates B-cell
receptor functions, vesicle transport, and intracellular trafficking [26–28]. In addition, CLL
lymphocytes are hypersensitive to apoptotic death activation through the specific inhibition
of proteasome [29,30]. Conversely, the stability of BCL6 is also reported to be regulated by
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ubiquitylation and proteasomal degradation in DLBCL [31]. Hence, there is a possibility
that BACH2 and BCL6 may be substrate adaptors for E3 ubiquitin ligases and involved in
proteosome mediated degradation processes in CLL.
The second largest group of proteins that interact with BACH2 and BCL6 belong to
nucleic acid metabolism (BCL6: MCM3, MCM4, BCL6 and BACH2: SSB, EXOSC6, FUBP1,
TCOF1, NUDT21, RAD23B). Mini-chromosome maintenance proteins (MCMs) are a family
of six structurally related helicases (MCM2–7) that play critical roles in DNA replication
and genome stability by forming a variety of complexes [32,33]. Each subunit of MCM has
distinct functions during the initiation, elongation, and termination processes of replication,
as well as in maintaining genomic stability [34]. Consequently, they have been implicated
in several cancers, including DLBCL [35]. In CLL, increased expression of MCM2, MCM3,
and MCM7 have been observed in primary samples from patients and two CLL-derived
cell lines (the MEC-1 and EHEB cell lines) [36]. Further, MCM7 suppression amplifies
replication stress and genomic instability and, in turn, hypersensitizes cells to certain drugs
such as fludarabine, which is used as a first-line therapy for CLL [36]. Thus, existing
reports and our findings indicate that the association between BCL6 and MCM components
influence novel regulatory mechanisms in DNA damage response and genome stability. In
the context of BACH2 in DNA damage, recent microarray studies have reported a strong
downregulation of BACH2 upon UV-induced damage or aging [37]. In addition to the
above identified major interaction networks, the interaction partner RAD23B, found in
our study, connects DNA repair and proteasome pathways [38]. The carboxy terminus of
RAD23B binds to the RAD4 DNA repair protein and the N terminal ubiquitin-like domain
interacts with the 26S proteasome and coordinates the regulation of these processes [39].
In the same theme of ubiquitination, genome stability, and DNA damage, TCOF1
(treacle ribosome biogenesis factor 1) has also been reported to function in ubiquitina-
tion through E3 ubiquitin ligase complex, RNA biogenesis, mitosis, proliferation, DNA
damage response, and apoptosis [40,41]. There are reports that connect FUBP1 (far up-
stream element binding protein 1) and NUDT21 to the RNA binding, polyadenylation, and
fine tuning of protein and RNA levels [41,42]. They both have been identified as potent
pro-proliferative and anti-apoptotic factors by the modulation of complex networks in
hematologic disorders and solid tumours [40,41]. Similarly, the BACH2–BCL6 interactors,
EXOCS2 and SSB, also reported to interact with RNA and EXOCS2, are part of the highly
conserved RNA processing/degrading exosome complex proteins in erythroid differentia-
tion [43,44]. Further, in the process of erythroid maturation blockade, GATA-1 and Foxo3
transcriptionally regulate exosome complex components and BACH2 has been reported to
function with both in T cell differentiation and homeostasis [45]. Thus, this collection of
interaction partners indicates cross communications mediated by BCL6 and BACH2 in key
genome stability, the ubiquitin-mediated protein degradation pathway, and homeostasis
processes in CLL.
4. Discussion
The precise cellular origin of CLL remains unclear and the current knowledge of
CLL biology demonstrates no direct link between the proliferative circulating CLL cells
to a specific normal B-cell subset [46,47]. B-cell associated gene-signatures are separated
based on pre- and post-GC B-lymphocytes (pre GC: pre-BI, pre-BII, and immature; post
GC: naïve, memory, or plasma cell subtypes) [47,48]. Several lines of evidence have
suggested that BCL6 and BACH2 cooperate in GC B-cells [49–51], thus understanding
the clinical significance of such transcriptional regulators in CLL patients and the protein
networks influenced by them is of high importance in CLL treatment. The expression
of BCL6 and the synergistic gene repression function of BCL6 and BACH2 are essential
for the highly complex GC formation process, which is orchestrated by key molecular
regulators such as MEF2B, IRF8, IRF4, BLIMP1, and TP53 [23,52]. Here, in this retrospective
study, we have investigated the clinical significance of BACH2 and BCL6 in a typical,
heterogenous CLL patient cohort that includes treatment naïve and treated subgroups. We
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have shown that low RNA expression of BACH2 and BCL6 predicts a shorter OS in IGHV-
M, 13q-deleted (regarded as a known low-risk subgroup), and 11q-deleted subgroups.
In addition, low BACH2 RNA and protein expression also predicted a shorter OS in
treatment naïve CLL patients. The number of treated and treatment naïve patients were
fairly equally distributed and balanced within most of the subgroups used in the univariate
and multivariate analyses (Tables 1, S1 and S2). However, when the number of patients
within the different molecular subgroups, such as IGHV-M, 13q-, and 11q-deleted, were
further divided based on treatment status, the number of patients in each subgroup (e.g.,
13q-deleted and 11q-deleted, high or low BACH2 expressing treatment naïve or treated
group, Table S2) were too small to perform meaningful analyses. Therefore, the BACH2
prognosticator role within these subgroups may be confounded by the treatment status of
the patients. However, the clear trend observed in this overall survival study suggests a
promising tumour suppressor function for BACH2 and BCL6. Although the relationship
between median progression-free survival (PFS)/time-to-progression (TTP) and median
overall survival in CLL appears to strongly correlate (in second- and subsequent-line
therapies, but not in the first-line setting), and PFS and TTP are suggested as possible
surrogates of overall survival [53], it was not possible to perform the progression-free
survival and time to first treatment analyses using this CLL study cohort due to the data
limitations.
The deletion of 13q14 is the most frequent genetic lesion in CLL, being most prevalent
in IGHV-M CLL [54,55]. It is noteworthy that the minimal region of 13q-deletion includes
micro RNAs, MIR15A–MIR161, that regulate cell cycle and apoptosis in B-cells [56–59].
Similarly, during the course of the B-cell development, BACH2 has also been reported
to play significant cell cycle and apoptotic regulatory roles [59–61], suggesting a possible
tumour suppressor function for BACH2 in good risk subgroups of CLL. In contrast, in
DLBCL, BACH2 expression has been reported as a predictor of poor prognosis, especially
in the high-risk group [14]. Although no direct experimental evidence on the mechanism
that identifies BACH2 as a poor prognosticator in DLBCL is available, these observations
are opposite to the those reported in this study. It is plausible that the expression of
the BACH2 regulator, PRDM1, or BLIMP1, which controls plasma cell differentiation, is
required for the terminal differentiation of B-cells, which is strongly suppressed by BACH2
in normal B-cell development. In DLBCL, the expression of PRDM1 appears to be very
weak in lymphoma cells, hence the constitutive expression of BACH2 may contribute to
maturation arrest of lymphoma cells, leading to lymphomagenesis. In CLL, a recent study
showed a decrease of BACH2 and an increase of PRDM1 in B-cells from CLL patients [52],
suggesting an opposite effect to DLBCL. However, further experiments and investigations
focused on additional clinical samples are essential to understand the seemingly distinct
BACH2–PRDM1 mediated regulatory mechanisms in DLBCL and CLL.
The prognostic role of BCL6 RNA and protein expression, as well as its mutational
status in CLL, have been investigated over the years with conflicting reports [54,62,63],
possibly resulting from differences in cell types tested and variations in the technologies
deployed [17,63–65]. The lack of correlation between the RNA and protein levels of BCL6
observed in our data is, however, not unusual [66,67], as the integration of transcrip-
tomic and proteomic data from normal as well as various cancer tissues have highlighted
the non-linear relationship between RNA and protein levels (i.e., ~60% of the variation
between RNA and protein abundances) [68,69]. This observation may result from the
complex, poorly understood intracellular transcriptional or post-transcriptional processes
that regulate the rates of RNA and protein production/turnover/stability and their mode
of regulation under different cellular conditions [66–69].
Our co-immunoprecipitation studies, performed in MEC1 CLL cells, show no direct
interaction between BACH2 and BCL6, but the majority of the interaction partners found
in the shared protein interaction network suggested cooperation between them in key
signalling processes, such as the ubiquitin-mediated protein degradation pathway, nucleic
acid metabolism, and cellular homeostasis (Table S7). Further, the interaction partners
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of BACH2 and BCL6 appeared to participate in cytoskeletal signalling, vesicle transport
molecules (BACH2: RHOG and DSP BCL6: ARF3, STXBP2, PHB2, and PSAP) and spliceo-
some machinery elements (BACH2: RETSAT, RPS14, SART3, BCL6: CTNNBL1). The
role of cytoskeletal signalling, vesicle transport, spliceosome machinery, and the ubiq-
uitin proteasome system in haematological malignancies, including CLL, has also been
suggested previously [70–73]. Further functional validation of these protein networks in
primary CLL cells and model systems is essential to determine the exact roles of BACH2
and BCL6 in CLL.
5. Conclusions
Taken together, our data for the first time demonstrate BACH2 as a possible indepen-
dent, integrative predictor of outcome in CLL. The clinical outcome and the proteomic
data highlight the tumour suppressor role and the functional significance of BACH2 and
BCL6 in CLL biology. Further investigations that study the impact of the BACH2 and BCL6
signalling axis will not only improve our understanding of CLL pathogenesis, but will also
offer new opportunities for novel targeted therapy development.
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cohorts (A). BACH2 protein expression does not predict outcome in immunoglobulin heavy chain
variable region-mutated (IGHV-M) patients (B), 13q-deleted (C), or 11q-deleted subgroups (D), Figure
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and BCL6, (A) BACH2 expression of treatment naïve arm, (B) BCL6 expression of treatment naïve
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WB original images, Table S1: Treatment regime of the thirty-five treated patients in this study,
Table S2: (A) The number of patients who had “high” and “low” BCL6 and BACH2 expression,
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